Analyst Ratings for Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Sarepta Therapeutics (NASDAQ:SRPT) has received various analyst ratings in the last quarter, with 3 bullish, 4 somewhat bullish, and 2 indifferent. Over the past 3 months, 9 analysts have offered 12-month price targets for the company, with an average price target of $111.67, a decrease of 30.04% from the previous average price target of $159.62.
November 02, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analyst ratings for Sarepta Therapeutics are mixed, with the average 12-month price target decreasing by 30.04% to $111.67.
The decrease in the average 12-month price target for Sarepta Therapeutics indicates a less optimistic outlook from analysts, which could negatively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100